RESOLUTION - ALKERMES, INC. - ARISTADA (ARIPIPRAZOLE LAUROXIL) .PDF

RESOLUTION: C-26-18-009-3-00
OUTPATIENT SAMPLE PROGRAM WITH ALKERMES, INC.
LONG ACTING INJECTABLE ANTIPSYCHOTIC MEDICATIONS
WHEREAS, an average of 200 inmate patients per month receive long acting injectable antipsychotic
(“LAI”) medications comprising of 20% of the monthly pharmacy budget for a jail population of 7500;
WHEREAS, recent medical literature indicates that adherence to antipsychotic medication may lead to a
decrease in criminal recidivism, and where patients are carefully selected for LAI treatment, in
combination with discharge planning and “warm handoffs,” there is the potential of decreasing the
recidivism of this vulnerable patient population;
WHEREAS, partnering with pharmaceutical companies to receive LAI medications free-of-charge,
Maricopa County Correctional Health Services will be able to continue these treatments on stable patients
and to initiate therapy on candidates who may benefit the most;
NOW THEREFORE:
BE IT RESOLVED that the Board of Supervisors hereby adopts Resolution: C-26-18-009-3-00 and authorizes
Maricopa County by and through its Department of Correctional Health Services (MCDCHS), to process a
non-financial Certification and Request form for ARISTADA® Samples with Alkermes, Inc.; for free samples
of ARISTADA®. Available doses in four (4) different strengths: 441mg, 662 mg, 882 mg and 1064 mg.
Dated this _______________________ day of _______________________________________, 2018.
IN WITNESS WHEREOF, the parties agree to enter into this agreement:
APPROVED AS TO FORM: FOR AND ON BEHALF OF
MARICOPA COUNTY
Attorney for Maricopa County By
Chairman, Board of Supervisors
Date
Date
ATTEST:
Clerk of the Board
Date